Enfusion, Inc. (NYSE:ENFN) Short Interest Update

Enfusion, Inc. (NYSE:ENFN) was the recipient of a large decline in short interest in November. As of November 30th, there was short interest totalling 820,400 shares, a decline of 19.6% from the November 15th total of 1,020,000 shares. Approximately 1.7% of the company’s stock are short sold. Based on an average trading volume of 404,000 shares, the short-interest ratio is currently 2.0 days.

Enfusion Stock Performance

Shares of NYSE:ENFN traded up $0.09 during trading on Friday, hitting $10.65. The company’s stock had a trading volume of 603,308 shares, compared to its average volume of 382,995. The company has a market capitalization of $1.37 billion, a PE ratio of 266.25, a PEG ratio of 3.98 and a beta of 0.97. Enfusion has a fifty-two week low of $7.52 and a fifty-two week high of $10.74. The stock’s 50-day moving average price is $9.53 and its two-hundred day moving average price is $8.96.

Insider Buying and Selling

In other Enfusion news, COO Neal Pawar sold 21,801 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.03, for a total value of $218,664.03. Following the completion of the transaction, the chief operating officer now directly owns 1,143,544 shares of the company’s stock, valued at $11,469,746.32. This represents a 1.87 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 36.44% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Enfusion

A number of institutional investors have recently made changes to their positions in ENFN. Barclays PLC increased its position in shares of Enfusion by 251.4% in the 3rd quarter. Barclays PLC now owns 86,039 shares of the company’s stock worth $817,000 after purchasing an additional 61,554 shares during the last quarter. Geode Capital Management LLC grew its stake in Enfusion by 7.3% in the third quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock worth $9,770,000 after purchasing an additional 70,367 shares in the last quarter. Wellington Management Group LLP increased its holdings in Enfusion by 6.7% in the third quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock valued at $9,265,000 after buying an additional 61,032 shares during the last quarter. TenCore Partners LP bought a new stake in Enfusion in the third quarter valued at about $3,938,000. Finally, State Street Corp raised its stake in Enfusion by 2.3% during the third quarter. State Street Corp now owns 952,895 shares of the company’s stock valued at $9,043,000 after buying an additional 21,729 shares in the last quarter. 81.05% of the stock is owned by institutional investors and hedge funds.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.